Attached files
| file | filename |
|---|---|
| EX-10.1 - GENVEC INC | v226093_ex10-1.htm |
| 8-K - GENVEC INC | v226093_8k.htm |
2011 Annual Stockholders Meeng
Safe Harbor Statement Statements herein relang to future financial or business performance, condions or strategies and other financial and business maers, including expectaons regarding future revenues and operang expenses, are forward-looking statements within the meaning of the Private Securies Ligaon Reform Act. GenVec cauons that these forward-looking statements are subject to numerous assumpons, risks and uncertaines, which change over me. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertaines, including the failure by GenVec to secure and maintain relaonships with collaborators; risks relang to clinical trials; risks relang to the commercializaon, if any, of GenVec’s proposed product candidates (such as markeng, regulatory, patent, product liability, supply, compeon and other risks); dependence on the efforts of third pares; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operaons. Further informaon on the factors and risks that could affect GenVec’s business; financial condions and results of operaons are contained in GenVec’s filings with the U.S. Securies and Exchange Commission (SEC), which are available at www.sec.gov. The forward-looking statements speak only as of the date of this presentaon, and GenVec assumes no duty to update forward-looking statements. June 15, 2011 Annual Stockholders Meeng 2
Key Points • Stock price – Gap between price and intrinsic value – Execute on the business plan – Educate invesng community • Business model • Upcoming milestones June 15, 2011 Annual Stockholders Meeng 3
GenVec Strategy Build shareholder value by Using differenated, proprietary technology to create superior therapeucs and vaccines that are developed and commercialized through collaboraons June 15, 2011 Annual Stockholders Meeng 4
Collaboraons Drive Development Human Therapeucs Human Vaccines Animal Health An Array of Product Programs Generated by GenVec’s Proprietary, Core Technology June 15, 2011 Annual Stockholders Meeng 5
A True Plaorm • Flexible, cost-effecve product discovery – Enables therapeucs and vaccines – Genes used to produce desired proteins – Rapid proof of concept tesng • Product candidates that meet partner’s needs – Address crical problems – Proprietary • Manufacturing, stability and safety advantages June 15, 2011 Annual Stockholders Meeng 6
GenVec Programs Human Vaccines Human Therapeucs Animal Health • RSV (NIH) • Hearing Loss & • FMD • Dengue Fever (NMRC Balance Disorders ─ Development & HJF) (Novars) (DHS) • Malaria (USMMVP) • TNFerade for Cancer ─ Commercial • HIV (NIH – VRC) (Merial) • HSV-2 • Swine diseases (Merial) June 15, 2011 Annual Stockholders Meeng 7
Recent Progress • Hearing loss: Manufacturing of clinical supplies • Dengue fever: New collaboraon and funding • RSV: Partnering efforts iniated • FMD: Commercializaon agreement with Merial • Viral diseases of swine: New Merial agreement June 15, 2011 Annual Stockholders Meeng 8
Key Objecves Vaccines Therapeucs Animal Health • RSV: Corporate • Advance hearing loss to • FMD: Field safety study collaboraon the clinic (Novars) (DHS) • Dengue fever: Animal • Collaboraon to develop • FMD: Animal tesng data (NMRC) TNFerade (Merial) • Malaria: Lead • Swine diseases: Iniate opmizaon (USMMVP) development program • HSV: Proof of concept (Merial) data June 15, 2011 Annual Stockholders Meeng 9
Financial Highlights Benefits of Collaboraons 2010 2011(proj) Revenues $16.5M $20-22M Cash Burn $10.7M $6-8M Cash (12/31) $35.2M $27-29M June 15, 2011 Annual Stockholders Meeng 10
HEARING LOSS AND BALANCE DISORDERS
Overview • 30- 40 million Americans could benefit from a mechanical device to assist hearing • Our innovave approach is first in class in a major commercial opportunity • Our collaborator, Novars, is a global leader in novel therapeucs • The lead candidate is advancing to the clinic June 15, 2011 Annual Stockholders Meeng 12
Novars Collaboraon • Novars responsible for worldwide development and commercializaon • Up to $213.6M in milestone payments • Royales on product sales • Addional $12.7M development agreement for supply of clinical materials June 15, 2011 Annual Stockholders Meeng 13
The Ear June 15, 2011 Annual Stockholders Meeng 14
The Problem: Loss of Sensory Cells • Trauma causes loss of sensory cells • Loss of cells causes loss of hearing Mild Loss • Mammals cannot regenerate sensory cells Severe Loss June 15, 2011 Annual Stockholders Meeng 15
Therapeuc Strategy: Generate New Sensory Cells • Convert supporng cells to needed sensory cells • Trigger conversion with the natural developmental regulator - Atonal protein • Deliver the Atonal gene to the supporng cells using an adenovector to produce the protein • Atonal protein induces sensory cell formaon June 15, 2011 Annual Stockholders Meeng 16
Regeneraon of Hair Cells Untreated Treated Izumikawa et al. Nature Medicine, 2005, 11(3): 271-276 June 15, 2011 Annual Stockholders Meeng 17
Regenerated Sensory Cells Aract Nerves Neuronal outgrowth New sensory cell Kawamoto et al. J. Neuroscience, 2003, 23(11): 4395-4400 June 15, 2011 Annual Stockholders Meeng 18
Treatment Restores Hearing Deafened Treated Guinea Pig Model Control ABR Threshold (dB SPL) 105 90 75 60 45 30 15 4 8 16 24 Frequency (kHz) Izumikawa et al. Nature Medicine, 2005, 11(3): 271-276 June 15, 2011 Annual Stockholders Meeng 19
Differenated Vaccines • Broadly applicable vaccine technology – Suite of vectors for gene delivery – Versale cell lines for vector producon – Smulaon of both arms of immune system • Vaccines that overcome known problems – Respiratory Syncyal Virus (RSV) – Foot and mouth disease (FMD) – Herpes simplex virus (HSV) June 15, 2011 Annual Stockholders Meeng 20
In Summary • Sustainable business strategy • Funded product pipeline with many upcoming development milestones • Emerging partnering opportunies • Solid financial posion: Greater than 3 years of operang capital June 15, 2011 Annual Stockholders Meeng 21